Early detection and treatment Archives

New treatment for Geographic Atrophy

January 30, 2025
Jennifer Zhao Zhao

The Therapeutic Goods Administration (TGA) approval of the new eye injection treatment SYFOVRE® (pegcetacoplan) is welcome news, as it will give many people with Geographic Atrophy a treatment option that they’ve never had before to slow the progression of the disease.

“Rural ophthalmologists are overloaded with patients. We need more specialists out here”

April 28, 2023
Michelle Hauschild

People who live in rural and remote areas face real struggles to commit to start sight-saving eye injections and to stick with the treatment.

“The cost of my eyes has prohibited us from going on any kind of holiday”

April 28, 2023
Michelle Hauschild

My eyes are our holiday money. I’ve even considered giving up my injections. It’s a

AREDS2 study confirms safety, efficacy of supplements

July 7, 2022
Tom Smith

Researchers confirm the AREDS2 formulation is safe for use over a decade.

“This is really good news”

April 18, 2022
Tom Smith

Eye injections have saved the sight of thousands of Australians since they arrived down under

Update: Potential new treatments for nAMD and DMO

February 21, 2022
Tom Smith

The US FDA recently approved two treatments: Susvimo® and Vabysmo®.

MDFA launches eye health video series

October 20, 2021
Michelle Hauschild

MDFA has released a new series of educational videos to help Aussies better understand macular disease.

Image of an older guy holding his glasses and looking at the camera

Third anti-VEGF agent reimbursed by PBS

October 18, 2021
Michelle Hauschild

Beovu has become the third anti-VEGF drug to be subsidised by the Pharmaceutical Benefits Scheme for the treatment of wet AMD.

Don’t defer essential eye appointments during lockdown

July 21, 2021
Michelle Hauschild

We’re seeking to clear up any confusion around deferring eye appointments during lockdown.

Interest: Early detection and treatment

AREDS2 study confirms safety, efficacy of supplements

MDFA launches eye health video series

Third anti-VEGF agent reimbursed by PBS

Follow us

Newsletter sign-up

Thank you.
Your contact form has been successfully submitted.

Unfortunately there are no matches for your search.

Please try another search term.

Thank you for your order!

Your pack will be sent in the next two business days.

Your expression of interest in our research grants program has been submitted.

We will be in touch at the next stage of the process.

Thank you for referring to MDFA for non-clinical support and macular disease information. We will be in contact in 2-3 business days.

Thank you for referring to MDFA for non-clinical support and macular disease information. We will be in contact in 2-3 business days.

Thank you for subscribing to MDFA’s newsletter/s.

You can opt-out at any time by contacting us on [email protected] or via our National Helpline: 1800 111 709.

Tell people about MDFA’s newsletters:

Thank you for subscribing to our newsletter.

You can opt-out at any time by contacting us on [email protected] or via our National Helpline: 1800 111 709.

Tell people about Macular Disease Foundation’s newsletters:

Thank you for subscribing to our newsletter.

You can opt-out at any time by contacting us on [email protected] or via our National Helpline: 1800 111 709.

Tell people about Macular Disease Foundation’s newsletters:

Thank you for subscribing to our newsletter.

You can opt-out at any time by contacting us on [email protected] or via our National Helpline: 1800 111 709.

Tell people about Macular Disease Foundation’s newsletters:

Thank you for registering for this event.

Let people know you're attending:

The is for health professionals only. Please enter your organisation and practitioner type to subscribe. If you are not a health professional, please untick this newsletter to continue.

Interest: Early detection and treatment

Follow us

Newsletter sign-up

Thank you.Your contact form has been successfully submitted.

Unfortunately there are no matches for your search.

Please try another search term.

Thank you for your order!

Your pack will be sent in the next two business days.

Your expression of interest in our research grants program has been submitted.

We will be in touch at the next stage of the process.

Thank you for referring to MDFA for non-clinical support and macular disease information. We will be in contact in 2-3 business days.

Thank you for referring to MDFA for non-clinical support and macular disease information. We will be in contact in 2-3 business days.

Thank you for subscribing to MDFA’s newsletter/s.

You can opt-out at any time by contacting us on [email protected] or via our National Helpline: 1800 111 709.Tell people about MDFA’s newsletters:

Thank you for subscribing to our newsletter.

You can opt-out at any time by contacting us on [email protected] or via our National Helpline: 1800 111 709.Tell people about Macular Disease Foundation’s newsletters:

Thank you for subscribing to our newsletter.

You can opt-out at any time by contacting us on [email protected] or via our National Helpline: 1800 111 709.Tell people about Macular Disease Foundation’s newsletters:

Thank you for subscribing to our newsletter.

You can opt-out at any time by contacting us on [email protected] or via our National Helpline: 1800 111 709.Tell people about Macular Disease Foundation’s newsletters:

Thank you for registering for this event.

Let people know you're attending:

The is for health professionals only. Please enter your organisation and practitioner type to subscribe. If you are not a health professional, please untick this newsletter to continue.

Thank you.
Your contact form has been successfully submitted.

You can opt-out at any time by contacting us on [email protected] or via our National Helpline: 1800 111 709.

Tell people about MDFA’s newsletters:

You can opt-out at any time by contacting us on [email protected] or via our National Helpline: 1800 111 709.

Tell people about Macular Disease Foundation’s newsletters:

You can opt-out at any time by contacting us on [email protected] or via our National Helpline: 1800 111 709.

Tell people about Macular Disease Foundation’s newsletters:

You can opt-out at any time by contacting us on [email protected] or via our National Helpline: 1800 111 709.

Tell people about Macular Disease Foundation’s newsletters: